公开(公告)号：EP1827492B1

公开(公告)日：2010-08-11

申请号：EP05852645.0

申请日：2005-11-30

申请人： Curagen Corporation ,  Abgenix, Inc.

发明人： RASTELLI, Luca ,  POLLACK, Vincent, A. ,  TSE, Kam, Fai ,  KLAKAMP, Scott ,  FOORD, Orit ,  LIANG, Meina ,  JIA, Xiao-Chi ,  XIAO, Feng ,  LICHENSTEN, Henri ,  HERRMANN, John ,  LAROCHELLE, William, J. ,  JEFFERS, Michael, E. ,  CHAPOVAL, Andrei ,  MEZES, Peter ,  ARA, Gulshan ,  TORGOV, Michael ,  KARKARIA, Cyrus ,  DAVAGNINO, Juan

IPC分类号： A61K39/395 ,  A61K47/48 ,  A61P35/00 ,  C07K16/30 ,  C07K19/00 ,  C12N1/21 ,  C12N15/13 ,  C12N15/63 ,  C12N5/10 ,  G01N33/574 ,  G01N33/577

CPC分类号： C07K16/3053 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/3061 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/62 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/94

摘要： The present invention provides fully human lonoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. the present invention futher provides bispecific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.

公开(公告)号：EP1827492A2

公开(公告)日：2007-09-05

申请号：EP05852645.0

申请日：2005-11-30

申请人： Curagen Corporation ,  Abgenix, Inc.

发明人： RASTELLI, Luca ,  POLLACK, Vincent, A. ,  TSE, Kam, Fai ,  KLAKAMP, Scott ,  FOORD, Orit ,  LIANG, Meina ,  JIA, Xiao-Chi ,  XIAO, Feng ,  LICHENSTEN, Henri ,  HERRMANN, John ,  LAROCHELLE, William, J. ,  JEFFERS, Michael, E. ,  CHAPOVAL, Andrei ,  MEZES, Peter ,  ARA, Gulshan ,  TORGOV, Michael ,  KARKARIA, Cyrus ,  DAVAGNINO, Juan

IPC分类号： A61K39/395 ,  A61K47/48 ,  A61P35/00 ,  C07K16/30 ,  C07K19/00 ,  C12N1/21 ,  C12N15/13 ,  C12N15/63 ,  C12N5/10 ,  G01N33/574 ,  G01N33/577

CPC分类号： C07K16/3053 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/3061 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/62 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/94

摘要： The present invention provides fully human lonoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. the present invention futher provides bispecific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.

公开(公告)号：EP1578799A2

公开(公告)日：2005-09-28

申请号：EP03796574.6

申请日：2003-12-02

申请人： Abgenix, Inc.

发明人： BABCOOK, John, S. ,  KANG, Jaspal, S. ,  FOORD, Orit ,  GREEN, Larry ,  FENG, Xiao ,  KLAKAMP, Scott ,  HAAK-FRENDSCHO, Mary ,  RATHANASWAMI, Palaniswami ,  PIGOTT, Craig ,  LIANG, Meina, L. ,  LEE, Rozanne ,  MANCHULENCHO, Kathy ,  FAGGIONI, Raffaella ,  SENALDI, Giorgio ,  QIAOJUAN, Jane, Su

IPC分类号： C07K16/00 ,  A61K39/395

CPC分类号： C07K16/241 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

摘要： Antibodies directed to the antigen TNFa and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNFa. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.

公开(公告)号：EP1639092A2

公开(公告)日：2006-03-29

申请号：EP04777147.2

申请日：2004-06-25

申请人： Abgenix, Inc.

发明人： WEBER, Richard ,  FENG, Xiao ,  FOORD, Orit ,  GREEN, Larry ,  GUDAS, Jean ,  KEYT, Bruce ,  LIU, Ying ,  RATHANASWAMI, Palani ,  RAYA, Robert ,  YANG, Xiao, Dong ,  CORVALAN, Jose ,  FOLTZ, Ian ,  JIA, Xiao-Chi ,  KANG, Jaspal ,  KING, Chadwick, T. ,  KLAKAMP, Scott, L. ,  SU, Qiaojuan, Jane

IPC分类号： C12N1/00

CPC分类号： C07K16/30 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6897 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/77 ,  C07K2317/92 ,  Y10S435/81

摘要： The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

公开(公告)号：EP1638606A2

公开(公告)日：2006-03-29

申请号：EP04777034.2

申请日：2004-06-25

申请人： Abgenix, Inc.

发明人： WEBER, Richard ,  FENG, Xiao ,  FOORD, Orit ,  GREEN, Larry ,  GUDAS, Jean ,  KEYT, Bruce ,  LIU, Ying ,  RATHANASWAMI, Palani ,  RAYA, Robert ,  YANG, Xiao, Dong ,  CORVALAN, Jose ,  FOLTZ, Ian ,  JIA, Xiao-Chi ,  KANG, Jaspal ,  KING, Chadwick, T. ,  KLAKAMP, Scott, L. ,  SU, Qiaojuan, Jane

IPC分类号： A61K39/395 ,  C07K16/28 ,  C07K17/00

CPC分类号： C07K16/30 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6897 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/77 ,  C07K2317/92 ,  Y10S435/81

摘要： The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

公开(公告)号：EP1542724A2

公开(公告)日：2005-06-22

申请号：EP03788686.8

申请日：2003-08-19

申请人： Abgenix, Inc.

发明人： GUDAS, Jean, M. ,  HAAK-FRENDSCHO, Mary ,  FOORD, Orit ,  LIANG, Meina, L. ,  AHLUWALIA, Kiran ,  BHAKTA, Sunil

IPC分类号： A61K39/395 ,  C07K16/00 ,  G01N33/53

CPC分类号： C07K16/24 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565

摘要： Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with some embodiments, there are provided fully human monoclonal antibodies directed to the antigen MCP-1. Nucelotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

公开(公告)号：EP1105427A2

公开(公告)日：2001-06-13

申请号：EP99943743.7

申请日：1999-08-17

申请人： Abgenix, Inc.

发明人： GALLO, Michael ,  JUNGHANS, Richard ,  FOORD, Orit

IPC分类号： C07K16/42 ,  C07K16/24 ,  C12N15/19 ,  C12N15/66

CPC分类号： C07K16/244 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2319/00

摘要： In accordance with the present invention, there are provided methods for the extension of serum half-lives of proteinaceous molecules, particularly antibody molecules, and compositions of molecules modified in accordance with the methods of the invention. In accordance with a first aspect of the present invention, there is provided a method of modifying the half-life of an antibody through providing an antibody containing an FcRn binding domain or the genes encoding such antibody and physically linking the antibody or the antibody as encoded to a second FcRn binding domain. In accordance with a second aspect of the present invention, there is provided a molecule that contains at least two distinct FcRn binding moieties.